IP Library Granted Patent US 7,718,705
Granted Patent B1
US 7,718,705 · App. 10/049,427 · Granted May 18, 2010

Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Assignee: Eli Lilly and Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,718,705
App. No.
10/049,427
Granted
May 18, 2010
Kind
B1
Abstract

Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.

Claims (10)

1. A method of treating or managing sexual dysfunction in a mammal in need of treatment which comprises administering on an as-needed basis to the mammal a therapeutically effective amount of dapoxetine or a pharmaceutically acceptable salt thereof, wherein the sexual dysfunction is premature ejaculation, wherein the mammal is a human male, and wherein said administration of dapoxetine is effective for treating or managing premature ejaculation in the absence of priming doses.

2. The method of claim 1 , wherein dapoxetine is administered immediately prior to, to about 12 hours prior to a sexual activity.

3. The method of claim 1 , wherein dapoxetine is administered immediately prior to, to about 8 hours prior to a sexual activity.

4. A method of treating or managing sexual dysfunction in a mammal in need of treatment which comprises administering on an as-needed basis to the mammal a therapeutically effective amount of dapoxetine or a pharmaceutically acceptable salt thereof, wherein the sexual dysfunction is premature ejaculation, wherein the mammal is a human male, wherein dapoxetine is administered immediately prior to, to about 4 hours prior to a sexual activity and wherein said administration of dapoxetine is effective for treating or managing premature ejaculation in the absence of priming doses.

5. The method of claim 1 , wherein dapoxetine is administered immediately prior to, to about 3 hours prior to a sexual activity.

6. The method of claim 1 , wherein dapoxetine is administered immediately prior to a sexual activity.

7. A method of treating premature ejaculation in a human male which comprises administering orally to the human male about 0.01 mg to about 200 mg of dapoxetine or a pharmaceutically acceptable salt thereof immediately prior to, to about 4 hours prior to a sexual activity, wherein said administration of dapoxetine is effective for treating premature ejaculation in the absence of priming doses.

8. A method of treating premature ejaculation in a human male which comprises administering orally to the human male about 0.01 mg to about 200 mg of dapoxetine or a pharmaceutically acceptable salt thereof immediately prior to, to about 3 hours prior to a sexual activity, wherein said administration of dapoxetine is effective for treating premature ejaculation in the absence of priming doses.

9. A method of treating premature ejaculation in a human male which comprises administering orally to the human male about 0.01 mg to about 200 mg of dapoxetine or a pharmaceutically acceptable salt thereof about 30 minutes to about 3 hours prior to a sexual activity, wherein said administration of dapoxetine is effective for treating premature ejaculation in the absence of priming doses.

10. A method of treating premature ejaculation in a human male which comprises administering orally to the human male about 0.01 mg to about 200 mg of dapoxetine or a pharmaceutically acceptable salt thereof immediately prior to a sexual activity, wherein said administration of dapoxetine is effective for treating premature ejaculation in the absence of priming doses.

Assignments (4)
MERGER Recorded Jun 26, 2018
From: APBI HOLDINGS, LLC
To: ALLERGAN SALES, LLC.
Reel/Frame 046207/0761 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 015238 FRAME 0544. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ADDRESS OF RECEIVING PARTY IS: 3151 SOUTH 17TH STREET WILMINGTON, NC 28412. Recorded Dec 1, 2004
From: ELI LILLY AND COMPANY
To: APBI HOLDINGS, LLC
Reel/Frame 015400/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2004
From: ELI LILLY AND COMPANY
To: APBI HOLDINGS, LLC
Reel/Frame 015328/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2002
From: THOR, KARL BRUCE
To: ELI LILLY AND COMPANY
Reel/Frame 012810/0088 →